Indications
• Adolescent type 2 diabetes(12-18 years,HbA1c≥6.5%)
• Prader-Willi syndrome-associated obesity(BMI ≥95th percentile for age)
Extended Indications
• Obesity-related obstructive sleep apnea(AHl index reduc- tion≥50%)
• Adolescent PCOS with insulin resistance(HOMA-IR≥2.5)
Features & Clinical Trial Data
1 Triple-Target Synergy:
• GLP-1R: Controls postprandial glucose (PPG reduction: 3.1 mmol/L).
• GIPR: 47% reduction in 24-hour hunger score (VAS scale).
• GCGR: 35% increase in resting energy expenditure (indirect calorimetry).
2 Upgraded Microneedle Technology:
• Proprietary soluble microneedle array (95% delivery efficiency).
• Rapid drug release within 10 minutes (in vitro dissolution verified).
• Flexible dosing range (2.5mg-10mg).
3 Comparative Advantages:
• 24-week BMI-SDS reduction: 1.5 vs. 1.0 for Tirzepatide (P=0.007).
• BMI reduction in severe obesity: 18.3% vs. 12.7% (DEXA-verified).
4 Key Trial (n=352):
• Adolescent group: 41% reduction in fasting insulin (vs. 28% for Tirzepatide group).
• Treatment satisfaction: 99.2% (vs. 81.4% for injection group).
• Room-temperature stability: 24 months
